Fenofibrate Associated With Reduced CV Disease in Diabetics

by U.S. Medicine

February 14, 2017

MEMPHIS—Cardiovascular risk is increased in patients with Type 2 diabetes, at least partly because of hypertriglyceridemia and low high-density lipoprotein cholesterol.

A study published online by JAMA Cardiology sought to determine if the risk is reduced by adding fenofibrate, which lowers triglycerides, to statin therapy.1

Researchers from the Memphis VAMC and the University of Tennessee Health Sciences Center, also in Memphis, and colleagues used a post-trial follow-up of the Action to Control Cardiovascular Risk in Diabetes Lipid Study to help answer the question. Results indicate that fenofibrate therapy was associated with reduced cardiovascular disease in study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL.

The extended post-trial follow-up of the ACCORD Lipid Study participants was conducted between July 2009 and October 2014 and involved 4,644 participants who were selected based on the presence of Type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55 mg/dL for women and African-American individuals).

In the passive follow-up of study participants previously treated with fenofibrate or masked placebo, researchers were looking for occurrence of cardiovascular outcomes, including primary composite outcome of fatal and nonfatal myocardial infarction and stroke in all participants and in pre-specified subgroups.

Researchers note that only 4.3% of study participants continued treatment with fenofibrate following completion of ACCORD and that high-density lipoprotein and triglyceride values rapidly equalized among participants originally randomized to fenofibrate or placebo.

Over a median total post-randomization follow-up of 9.7 years, the hazard ratio (HR) for the primary study outcome among participants originally randomized to fenofibrate vs placebo, 0.93, was comparable with that originally observed in ACCORD, 0.92.

“Despite these overall neutral results, we continued to find evidence that fenofibrate therapy effectively reduced CVD in study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL (HR, 0.73; 95% CI, 0.56-0.95),” according to study authors.

  1. Elam MB, Ginsberg HN, Lovato LC, Corson M, et. al. ACCORDION Study Investigators. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2016 Dec 28. doi: 10.1001/jamacardio.2016.4828. [Epub ahead of print] PubMed PMID: 28030716.

Comments are closed here.

Related Articles

Is Prandial Insulin or Noninsulin Agent Better for T2D Treatment Intensification?

Some veterans with type 2 diabetes patients can't reach their hemoglobin A1c goal despite using metformin, basal insulin and a sulfonylurea. What should come next?

Caution Urged in Use of Sulfonylureas in Some T2 Diabetes Patients with CAD

VA clinicians should exercise caution with use of sulfonylurea in some patients with co-morbid type 2 diabetes and cardiovascular disease, according to new research.

U.S. Medicine Recommends

More From department of veterans affairs

Department of Veterans Affairs (VA)

Senate VA Committee Chair Vows to Pass 'Blue Water' Navy Benefits

Senate Committee on Veterans' Affairs Chairman Sen. Johnny Isakson (R-GA) vowed that addressing benefits for Blue Water Navy Veterans “is no longer going to be a question,” but that “how we do it is the only question.”

Department of Veterans Affairs (VA)

VHA Makes Progress in Improving Safety of Opioid Prescribing

VHA medical facilities should ensure that its providers are following three key opioid risk mitigation strategies, including conducting urine drug screening, a recent report recommended.

Department of Veterans Affairs (VA)

VA faces healthcare staffing shortages, barriers to hiring facility leaders

A facility-specific survey found that 138 of 140 VA facilities reported shortages of medical officers, with psychiatry and primary care positions being the most frequently listed.

Department of Veterans Affairs (VA)

Veteran nephrologist labors to improve ESRD treatment at VA

When Terrence O’Neil, MD, retired as chief of nephrology at the James H. Quillen VAMC in Johnson City in December 2016, he left in his wake decades of work treating kidney disease—nearly 35 years in the Air Force and DoD, plus 11 more at VA.

Department of Veterans Affairs (VA)

Committee approves bill to provide agent orange benefits to ‘blue water’ vets

A long sought-after bill that would make it easier for Blue Water Navy veterans to receive Agent Orange benefits has been passed by a key House of Representatives committee.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up